Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Spok Holdings, Inc.

SPOK
Healthcare · Health Information Services

Spok Holdings, Inc. is printing record margins on a fuller multiple. From here the earnings must do all the lifting.

The sharpest disagreement: annual EPS moved +2.7% against a −39.4% price move — the market has not yet caught up with the delivery.

The price is between stages while the P/E sits at the 74th percentile of its own 1-year range. Underneath, the last four quarters read deteriorating — profit −100.0% year on year, and 180% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Mixed
partial read
Price
$11.2
−39.4% 1Y
P/E
19.6×
74th pctile
of its own 1-year range
Revenue (Mar 26)
$0.0 B
−25.0% YoY
Profit (Mar 26)
$0.0 B
−100.0% YoY
Operating margin
0.0%
−25.0 pp YoY
ROE
8%
FY25
ROIC
10.2%
vs WACC 6.5% → +3.7 pp
Cash conversion
180%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Spok Holdings, Inc. trades at $11.2, between stages. That is −8.0% against its own 200-day average. It sits at 10% of a 52-week range of $10 to $18. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (24 weeks and counting).

Today the stock is between stages. At $11.2 it trades −8.0% versus its 200-day average and sits at 10% of its 52-week range ($10–$18).

Aug 26: $11.2 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
−8.0% versus the 200-day line, week — of stage —
Price50-day avg200-day avg
$19.2$16.8$14.5$12.1$9.8$$11$12Jul 25Oct 25Jan 26May 26Aug 26
$19.2$16.8$14.5$12.1$9.8$$11$12Jul 25Jan 26Aug 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (57 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 25Aug 26

Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved −36% while the S&P 500 moved +24% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (24 weeks and counting; last ahead the week of 2026-02-20) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Spok Holdings, Inc. trades at 19.6× P/E, at the pricey end of its own range (74th percentile). Its long-run median P/E is 17.9×, measured across 1.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 19.6× is at the pricey end of its own range (74th percentile), against a long-run median of 17.9× measured over 1.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 19.6× vs a 17.9× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 1.1-year window; loss-period spikes above 22× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
at the pricey end of its own range (74th percentile)
P/EMedianEPS (TTM) (quarterly)
22.8×$0.920.6×$0.718.4×$0.416.2×$0.213.9×$0.0×$18.68×$1Jul 25Oct 25Jan 26May 26Aug 26
22.8×$0.920.6×$0.718.4×$0.416.2×$0.213.9×$0.0×$18.68×$1Jul 25Jan 26Aug 26
P/E
19.6×
74th percentile of 1y
PEG
n/m
not derivable — 3-year earnings growth unavailable

Why the multiple sits where it does: over the past year annual EPS moved +2.7% against a −39.4% price move — earnings outran the price, pushing the multiple DOWN its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Spok Holdings, Inc. reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE slipping at 6.5% — the per-curve reads carry the story. The read is built from 12 quarters across 3 curves, on partial evidence.

Growth, year by year: revenue +0.0% in FY25, profit +100.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
8.9%112%4.6%69%0.3%25%−4.0%−19%−8.3%−62%%%0%100%FY21FY23FY25
8.9%112%4.6%69%0.3%25%−4.0%−19%−8.3%−62%%%0%100%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue accelerating
RevenueProfitEPS
19%18%10%−13%1.2%−45%−7.8%−77%−17%−109%%%0%−100%−23.1%Jun 23Sep 24Mar 26
19%18%10%−13%1.2%−45%−7.8%−77%−17%−109%%%0%−100%−23.1%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
13%9.6%6.0%2.5%−1.0%%6.5%Jun 23Dec 23Sep 24Jun 25Mar 26
13%9.6%6.0%2.5%−1.0%%6.5%Jun 23Sep 24Mar 26
Revenue growth
Flat
latest +0.0% · span −14.3% to +16.7%
EPS growth
Falling
latest −23.1% · span −59.7% to +9.6%
ROCE
Falling
latest 6.5% · span 0.0%–12.1%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+0.0%+2.5%
Profit+100.0%+0.0%
EPS+2.7%−11.7%
Stock price−39.4%
Revenue YoY (Mar 26)
−25.0%
latest quarter vs a year ago
Profit YoY (Mar 26)
−100.0%
latest quarter vs a year ago
Revenue 10y
0.0%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

36.0/100 — rank 24 of 29 in Health Information Services · 75% evidence confidence

Spok Holdings, Inc. scores 36.0 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 24. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 8.4 + 13 + 9.7 + 4.9 = 36. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Spok Holdings, Inc. reported $0.0 B of revenue in the Mar 26 quarter, −25.0% year on year. Over 4 years it has compounded at 0.0% a year. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.1 B.

FY25 revenue came in at $0.1 B (+0.0% on the year), capping 4 years at 0.0% compound. The latest quarter (Mar 26) printed $0.0 B, −25.0% year on year.

FY25 revenue $0.1 B (+0.0% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
0.0% a year over 4 years
RevenueYoY growth
0.158.9%0.114.6%0.080.3%0.04−4.0%0.00−8.3%$ B%$0B0%FY21FY23FY25
0.158.9%0.114.6%0.080.3%0.04−4.0%0.00−8.3%$ B%$0B0%FY21FY23FY25
Mar 26: $0.0 B (−25.0% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
0.0438%0.0321%0.024.1%0.01−13%0.00−30%$ B%$0B−25%Jun 23Sep 24Mar 26
0.0438%0.0321%0.024.1%0.01−13%0.00−30%$ B%$0B−25%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +2.1% growth against the decade's 0.0% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +0.0% over the last 4 quarters against −3.6%/yr over the last 8 — accelerating.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Spok Holdings, Inc.'s operating margin is 0.0% in the Mar 26 quarter, −25.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −21.4% to 14.3%. The current quarter sits inside that band.

The latest quarter's operating margin is 0.0%, −25.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −21.4%–14.3%, and FY25's 14.3% is the top of that band — a record year.

🚨 Why the margin moved: operating margin went −25.0 pp year on year while gross margin went +25.0 pp — the loss came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY25: 14.3% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
the widest a −21.4–14.3% band over 5 years
operating marginYoY change (pp)
17%23%6.8%17%−3.6%11%−14%4.5%−24%−1.7%%%14.3%0%FY21FY23FY25
17%23%6.8%17%−3.6%11%−14%4.5%−24%−1.7%%%14.3%0%FY21FY23FY25
Mar 26: 0.0% operating margin (−25.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
27%29%20%15%13%0.0%5.3%−15%−2.0%−29%%%0%−25%Jun 23Sep 24Mar 26
27%29%20%15%13%0.0%5.3%−15%−2.0%−29%%%0%−25%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Spok Holdings, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −100.0% year on year. Full-year FY25 profit was $0.0 B. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.

Mar 26 profit was $0.0 B, −100.0% year on year. On the full year, FY25 printed $0.0 B (+100.0%).

FY25 profit $0.0 B (+100.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
0.02112%0.0169%0.0025%−0.01−19%−0.02−62%$ B%$0B100%FY21FY23FY25
0.02112%0.0169%0.0025%−0.01−19%−0.02−62%$ B%$0B100%FY21FY23FY25
Mar 26: $0.0 B (−100.0% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.011−98.8%0.008−99.4%0.005−100.0%0.003−100.6%0.000−101.2%$ B%$0B−100%Jun 23Sep 24Mar 26
0.011−98.8%0.008−99.4%0.005−100.0%0.003−100.6%0.000−101.2%$ B%$0B−100%Jun 23Sep 24Mar 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 180% of Spok Holdings, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.0 B was left as free cash.

FY25: operating cash of $0.0 B against reported profit of $0.0 B, leaving free cash of $0.0 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 180% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.0 B vs profit $0.0 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
180% of 3-year profit arrived as cash
Operating cashNet profitFree cash
0.030.020.01−0.01−0.02$ B$0B$0B$0BFY21FY23FY25
0.030.020.01−0.01−0.02$ B$0B$0B$0BFY21FY23FY25
Mar 26: operating cash $0.0 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.011108%0.00879%0.00550%0.00321%0.000−8.0%$ B%$0B0%Jun 23Sep 24Mar 26
0.011108%0.00879%0.00550%0.00321%0.000−8.0%$ B%$0B0%Jun 23Sep 24Mar 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Spok Holdings, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
1.20.60.0−0.6−1.2$ B$0BFY21FY23FY25
1.20.60.0−0.6−1.2$ B$0BFY21FY23FY25
Mar 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
1.20.0110.60.0080.00.005−0.60.002−1.2−0.001$ B$ B$0B$0BJun 23Sep 24Mar 26
1.20.0110.60.0080.00.005−0.60.002−1.2−0.001$ B$ B$0B$0BJun 23Sep 24Mar 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Spok Holdings, Inc. earns a ROE of 13% in FY25. That is up from a trough of −12% in FY21. Return on invested capital clears the cost of that capital by +3.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.3% net margin on 0.67× asset turns.

FY25 ROE is 13%, recovered from a FY21 trough of −12% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 14.3% net margin × 0.67× asset turns × 1.40× balance-sheet leverage ≈ 13.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 10.2% − 6.5% = a +3.7 pp spread. The 6.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY25: ROE 13% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 6.5% cost of capital used on this page.
the climb back from FY21's −12%
ROEROIC (annual)WACC
16%7.0%−1.8%−10%−19%%13.3%11.1%FY21FY23FY25
16%7.0%−1.8%−10%−19%%13.3%11.1%FY21FY23FY25
Mar 26: ROIC 8.5% (TTM) vs WACC 6.5% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
25%20%15%10%5.2%%8.5%8.3%Jun 23Sep 24Mar 26
25%20%15%10%5.2%%8.5%8.3%Jun 23Sep 24Mar 26
11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Spok Holdings, Inc. paid $1.25 per share over the last four reported quarters. The most recent declaration was $0.31 for Mar 26. Against the current price of $11.2 that is a trailing yield of 11.15%, measured on dividends already paid rather than on a forecast.

Spok Holdings, Inc. paid $1.25 per share across the last four reported quarters, most recently $0.31 for Mar 26. Against the current price of $11.2 the trailing twelve months work out to 11.15% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 12 quarters on file.
latest $0.31 (Mar 26)
Dividend per share
0.340.250.170.080.00$ B$0BJun 23Dec 23Sep 24Jun 25Mar 26
0.340.250.170.080.00$ B$0BJun 23Sep 24Mar 26
12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Spok Holdings, Inc. carries total debt of $0.0 B against shareholder equity of $0.1 B as of Mar 26, a debt-to-equity of 0.07 — effectively unlevered. On the annual view that ratio went from 0.12 in FY21 to 0.07 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of $0.0 B against shareholder equity of $0.1 B — a debt-to-equity of 0.07. On the annual view, debt-to-equity went from 0.12 (FY21) to 0.07 (FY25). The returns on this page are earned, not borrowed.

FY25: debt $0.0 B at 0.07× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
0.0220.12×0.0160.11×0.0110.09×0.0050.07×0.0000.06×$ B×$0B0.07×FY21FY23FY25
0.0220.12×0.0160.11×0.0110.09×0.0050.07×0.0000.06×$ B×$0B0.07×FY21FY23FY25
Mar 26: debt $0.0 B, debt-to-equity 0.07 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
0.0110.071×0.0080.068×0.0050.065×0.0030.062×0.0000.059×$ B×$0B0.07×Jun 23Sep 24Mar 26
0.0110.071×0.0080.068×0.0050.065×0.0030.062×0.0000.059×$ B×$0B0.07×Jun 23Sep 24Mar 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

3.1% of Spok Holdings, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.9 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 3.1% of the float is sold short, and at typical trading volumes it would take about 2.9 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
3.1%
of the tradable float
Days to cover
2.9
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Spok Holdings, Inc.: the Z-score reads 4.36. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 4.36 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 4.36.

15 · Related companies · Health Information Services
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1HealthEquity, Inc.HQY 67.9/100Favorable setup85% evidence BREAKING OUT 23.6/35 Revenue 7.6% · PAT 89.3% · OPM change 3.9 pp 95% evidence 15.5/25 ROCE 3.2% · OPM 29% 76% evidence 12.4/20 P/E 30.7× · PEG 1.57 65% evidence 16.4/20 RS sector 4.3% · RS bench 5.3% · 1Y 12.8%5 of 12 weeks ahead 100% evidence
Exact sum: 23.6 + 15.5 + 12.4 + 16.4 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Simulations Plus, Inc.SLP 64.2/100Thin evidence · provisional52% evidence LEADER 24.6/35 Revenue — · PAT — · OPM change 11.1 pp 45% evidence 16.2/25 ROCE 3.4% · OPM 23.2% 76% evidence 10.3/20 P/E 42.8× · PEG — 15% evidence 13.1/20 RS sector 2.4% · RS bench 3.2% · 1Y 29.5%12 of 12 weeks ahead 70% evidence
Exact sum: 24.6 + 16.2 + 10.3 + 13.1 = 64.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Hinge Health, Inc.HNGE 61.7/100Mixed-positive evidence62% evidence LEADER 19.9/35 Revenue 49.5% · PAT -1748.4% · OPM change 7 pp 83% evidence 15.1/25 ROCE 8.4% · OPM 17.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 16.7/20 RS sector 35% · RS bench 35.8% · 1Y 40.1%12 of 12 weeks ahead 70% evidence
Exact sum: 19.9 + 15.1 + 10 + 16.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Veeva Systems Inc.VEEV 61.5/100Mixed-positive evidence85% evidence BREAKING OUT 20.5/35 Revenue 16.3% · PAT 20.5% · OPM change 0.1 pp 95% evidence 17.7/25 ROCE 4% · OPM 30.9% 76% evidence 13.8/20 P/E 27.8× · PEG 1.47 65% evidence 9.5/20 RS sector -12.6% · RS bench -13% · 1Y -24.9%5 of 12 weeks ahead 100% evidence
Exact sum: 20.5 + 17.7 + 13.8 + 9.5 = 61.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
510x Genomics, Inc.TXG 56.9/100Mixed-positive evidence61% evidence LEADER 20.1/35 Revenue 2.2% · PAT — · OPM change 14.1 pp 62% evidence 6.8/25 ROCE -2% · OPM -11.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 20.0/20 RS sector 91.7% · RS bench 96.6% · 1Y 289.4%12 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 6.8 + 10 + 20 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6BrightSpring Health Services, Inc.BTSG 56.2/100Thin evidence · provisional58% evidence LEADER 19.7/35 Revenue — · PAT — · OPM change 1.6 pp 45% evidence 12.7/25 ROCE 2.9% · OPM 3.4% 76% evidence 10.1/20 P/E 44.4× · PEG — 15% evidence 13.7/20 RS sector 27.5% · RS bench 31.3% · 1Y 202.1%12 of 12 weeks ahead 100% evidence
Exact sum: 19.7 + 12.7 + 10.1 + 13.7 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7HealthStream, Inc.HSTM 55.8/100Mixed-positive evidence81% evidence BREAKING OUT 19.0/35 Revenue 6.5% · PAT 5.3% · OPM change 3.3 pp 83% evidence 14.2/25 ROCE 1.9% · OPM 9.3% 76% evidence 5.6/20 P/E 30.9× · PEG 4.87 65% evidence 17.0/20 RS sector 8.6% · RS bench 9.2% · 1Y 14.7%11 of 12 weeks ahead 100% evidence
Exact sum: 19 + 14.2 + 5.6 + 17 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Omada Health, Inc.OMDA 53.6/100Thin evidence · provisional55% evidence BREAKING OUT 25.2/35 Revenue 49% · PAT — · OPM change 9.2 pp 62% evidence 7.0/25 ROCE -2.9% · OPM -6.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 11.4/20 RS sector 1.2% · RS bench 0.6% · 1Y 6.1%12 of 12 weeks ahead 70% evidence
Exact sum: 25.2 + 7 + 10 + 11.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Phreesia, Inc.PHR 49.2/100Mixed-negative evidence67% evidence BREAKING OUT 22.7/35 Revenue 13.8% · PAT 100% · OPM change 8 pp 71% evidence 10.9/25 ROCE 1.7% · OPM 5.2% 76% evidence 9.7/20 P/E 61.4× · PEG — 15% evidence 5.9/20 RS sector -34.4% · RS bench -35.7% · 1Y -57.6%5 of 12 weeks ahead 100% evidence
Exact sum: 22.7 + 10.9 + 9.7 + 5.9 = 49.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Omnicell, Inc.OMCL 47.3/100Thin evidence · provisional58% evidence ASLEEP 21.4/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence 12.8/25 ROCE 2.1% · OPM 5.4% 76% evidence 9.9/20 P/E 49.4× · PEG — 15% evidence 3.2/20 RS sector -15.2% · RS bench -13.5% · 1Y 20.5%5 of 12 weeks ahead 100% evidence
Exact sum: 21.4 + 12.8 + 9.9 + 3.2 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11SOPHiA GENETICS SASOPH 47.0/100Thin evidence · provisional55% evidence BREAKING OUT 17.4/35 Revenue 19.1% · PAT — · OPM change 10.5 pp 62% evidence 3.6/25 ROCE -15.1% · OPM -79.7% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 16.0/20 RS sector 26.6% · RS bench 29.3% · 1Y 115.1%6 of 12 weeks ahead 70% evidence
Exact sum: 17.4 + 3.6 + 10 + 16 = 47 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Weave Communications, Inc.WEAV 46.5/100Thin evidence · provisional55% evidence BREAKING OUT 21.7/35 Revenue 16.4% · PAT — · OPM change 7.5 pp 62% evidence 5.6/25 ROCE -5.1% · OPM -9.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.2/20 RS sector -2.5% · RS bench -2.2% · 1Y -9.2%8 of 12 weeks ahead 70% evidence
Exact sum: 21.7 + 5.6 + 10 + 9.2 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Waystar Holding Corp.WAY 46.1/100Thin evidence · provisional58% evidence TURNING 16.6/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence 12.6/25 ROCE 1.5% · OPM 25.6% 76% evidence 11.0/20 P/E 29.3× · PEG — 15% evidence 5.9/20 RS sector -25.5% · RS bench -25.7% · 1Y -31.3%1 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 12.6 + 11 + 5.9 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14NRC HealthNRC 45.7/100Thin evidence · provisional52% evidence FADING 12.6/35 Revenue — · PAT — · OPM change -9.6 pp 45% evidence 11.5/25 ROCE -3.1% · OPM 16% 76% evidence 9.0/20 P/E 86.3× · PEG — 15% evidence 12.6/20 RS sector 1.5% · RS bench 3.4% · 1Y 29.7%9 of 12 weeks ahead 70% evidence
Exact sum: 12.6 + 11.5 + 9 + 12.6 = 45.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15TruBridge, Inc.TBRG 45.3/100Thin evidence · provisional58% evidence 10.9/35 Revenue 0% · PAT — · OPM change -5.9 pp 62% evidence 10.0/25 ROCE 0.9% · OPM 3.5% 76% evidence 9.2/20 P/E 73.2× · PEG — 15% evidence 15.2/20 RS sector 5.2% · RS bench 11% · 1Y 18.9%8 of 8 weeks ahead to 2026-07-10 70% evidence
Exact sum: 10.9 + 10 + 9.2 + 15.2 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Carlsmed, Inc.CARL 45.2/100Thin evidence · provisional55% evidence BREAKING OUT 21.3/35 Revenue 75% · PAT — · OPM change -1.5 pp 62% evidence 4.2/25 ROCE -11.7% · OPM -57.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.7/20 RS sector -2.3% · RS bench -1.5% · 1Y 5.6%4 of 12 weeks ahead 70% evidence
Exact sum: 21.3 + 4.2 + 10 + 9.7 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Privia Health Group, Inc.PRVA 44.2/100Mixed-negative evidence81% evidence ASLEEP 22.8/35 Revenue 24.7% · PAT 40% · OPM change 0.1 pp 83% evidence 11.1/25 ROCE 1% · OPM 1.2% 76% evidence 4.7/20 P/E 128.6× · PEG 3.86 65% evidence 5.6/20 RS sector -10.3% · RS bench -9.2% · 1Y 15.6%4 of 12 weeks ahead 100% evidence
Exact sum: 22.8 + 11.1 + 4.7 + 5.6 = 44.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.3% and the one-year return is 15.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
18GoodRx Holdings, Inc.GDRX 42.2/100Mixed-negative evidence65% evidence BREAKING OUT 8.6/35 Revenue -1.3% · PAT -31% · OPM change -4.3 pp 83% evidence 11.0/25 ROCE 1.2% · OPM 7.2% 76% evidence 10.4/20 P/E 32.7× · PEG — 15% evidence 12.2/20 RS sector 1.7% · RS bench 1% · 1Y -3.7%11 of 12 weeks ahead 70% evidence
Exact sum: 8.6 + 11 + 10.4 + 12.2 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Doximity, Inc.DOCS 40.7/100Mixed-negative evidence81% evidence ASLEEP 11.6/35 Revenue 13% · PAT -11.7% · OPM change -18.1 pp 83% evidence 15.9/25 ROCE 2.4% · OPM 17.1% 76% evidence 11.3/20 P/E 23.8× · PEG 1.84 65% evidence 1.9/20 RS sector -49.3% · RS bench -50.6% · 1Y -67.1%0 of 12 weeks ahead 100% evidence
Exact sum: 11.6 + 15.9 + 11.3 + 1.9 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Talkspace, Inc.TALK 40.6/100Mixed-negative evidence64% evidence ASLEEP 12.9/35 Revenue 22.7% · PAT -66.7% · OPM change -9.5 pp 62% evidence 6.0/25 ROCE -6.2% · OPM -11.6% 76% evidence 8.5/20 P/E 517.5× · PEG — 15% evidence 13.2/20 RS sector 8.3% · RS bench 12% · 1Y 106%0 of 12 weeks ahead 100% evidence
Exact sum: 12.9 + 6 + 8.5 + 13.2 = 40.6 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
21HeartFlow, Inc.HTFL 39.7/100Thin evidence · provisional55% evidence ASLEEP 20.1/35 Revenue 40.4% · PAT — · OPM change -9.1 pp 62% evidence 4.0/25 ROCE -13.2% · OPM -56.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 5.6/20 RS sector -18% · RS bench -17.4% · 1Y -12.5%6 of 12 weeks ahead 70% evidence
Exact sum: 20.1 + 4 + 10 + 5.6 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22Schrödinger, Inc.SDGR 37.5/100Thin evidence · provisional58% evidence BREAKING OUT 15.8/35 Revenue 10.9% · PAT — · OPM change 2.2 pp 62% evidence 4.9/25 ROCE -9.4% · OPM -83.3% 76% evidence 9.6/20 P/E 66.3× · PEG — 15% evidence 7.2/20 RS sector -11.9% · RS bench -12.2% · 1Y -18.5%10 of 12 weeks ahead 70% evidence
Exact sum: 15.8 + 4.9 + 9.6 + 7.2 = 37.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Tempus AI, Inc.TEM 37.1/100Thin evidence · provisional55% evidence ASLEEP 19.0/35 Revenue — · PAT — · OPM change 2.6 pp 45% evidence 5.4/25 ROCE -4.8% · OPM -24.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 2.7/20 RS sector -32.9% · RS bench -33.2% · 1Y -22.7%3 of 12 weeks ahead 100% evidence
Exact sum: 19 + 5.4 + 10 + 2.7 = 37.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24Spok Holdings, Inc.this pageSPOK 36.0/100Mixed-negative evidence75% evidence BASING 8.4/35 Revenue -1.4% · PAT -18.8% · OPM change -9.2 pp 83% evidence 13.0/25 ROCE 1.6% · OPM 7.4% 76% evidence 9.7/20 P/E 18.2× · PEG 2.25 65% evidence 4.9/20 RS sector -23.7% · RS bench -23.5% · 1Y -38.4%0 of 12 weeks ahead 70% evidence
Exact sum: 8.4 + 13 + 9.7 + 4.9 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Claritev CorporationCTEV 36.0/100Thin evidence · provisional55% evidence ASLEEP 13.1/35 Revenue 5.8% · PAT — · OPM change -3.1 pp 62% evidence 8.9/25 ROCE 0.1% · OPM 2.7% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 4.0/20 RS sector -33.5% · RS bench -35.5% · 1Y -53.5%8 of 12 weeks ahead 70% evidence
Exact sum: 13.1 + 8.9 + 10 + 4 = 36 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26Certara, Inc.CERT 35.6/100Thin evidence · provisional58% evidence BREAKING OUT 12.0/35 Revenue 6.8% · PAT — · OPM change -11.2 pp 62% evidence 8.8/25 ROCE -0.3% · OPM -4% 76% evidence 8.7/20 P/E 174.6× · PEG — 15% evidence 6.1/20 RS sector -14.8% · RS bench -15.5% · 1Y -28.7%6 of 12 weeks ahead 70% evidence
Exact sum: 12 + 8.8 + 8.7 + 6.1 = 35.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Evolent Health, Inc.EVH 32.7/100Thin evidence · provisional55% evidence ASLEEP 11.3/35 Revenue -21.3% · PAT — · OPM change -1.8 pp 62% evidence 8.1/25 ROCE -0.6% · OPM -2.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 3.3/20 RS sector -42.2% · RS bench -43.6% · 1Y -65.4%10 of 12 weeks ahead 70% evidence
Exact sum: 11.3 + 8.1 + 10 + 3.3 = 32.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28LifeMD, Inc.LFMD 31.0/100Thin evidence · provisional58% evidence ASLEEP 12.3/35 Revenue 36.9% · PAT — · OPM change -15.5 pp 62% evidence 4.0/25 ROCE -53.7% · OPM -17.8% 76% evidence 9.4/20 P/E 72.2× · PEG — 15% evidence 5.3/20 RS sector -21.5% · RS bench -21.8% · 1Y -42.8%7 of 12 weeks ahead 70% evidence
Exact sum: 12.3 + 4 + 9.4 + 5.3 = 31 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Teladoc Health, Inc.TDOC 41.9/100Thin evidence · provisional49% evidence ASLEEP 18.6/35 Revenue — · PAT — · OPM change 9.1 pp 45% evidence 6.8/25 ROCE -1.9% · OPM -10.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 6.5/20 RS sector -14.6% · RS bench -14.6% · 1Y -3.6%10 of 12 weeks ahead 70% evidence
Exact sum: 18.6 + 6.8 + 10 + 6.5 = 41.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Spok Holdings, Inc.'s stock price today?

Spok Holdings, Inc. trades at $11.2, −39.4% over the past year. The company is valued at $0.0 B. The stock sits at 10% of its 52-week range of $10–$18, −8.0% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 24 weeks. — as of 5 August 2026.

What were Spok Holdings, Inc.'s latest quarterly results?

Spok Holdings, Inc. reported revenue of $0.0 B and net profit of $0.0 B for the Mar 26 quarter. Revenue fell 25.0% and profit fell 100.0% year on year. Earnings per share were $0.09. The operating margin was 0.0%, 25.0 pp lower than a year earlier. — as of 5 August 2026.

What is Spok Holdings, Inc.'s revenue?

Spok Holdings, Inc. reported revenue of $0.0 B in the Mar 26 quarter, −25.0% year on year. For the full FY25 fiscal year, revenue was $0.1 B (+0.0%). Over the last 4 years revenue compounded at 0.0% a year. — as of 5 August 2026.

What is Spok Holdings, Inc.'s profit?

Spok Holdings, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −100.0% year on year. Full-year FY25 profit was $0.0 B. The operating margin ran 0.0% in the latest quarter. — as of 5 August 2026.

What is Spok Holdings, Inc.'s market cap?

Spok Holdings, Inc.'s market capitalisation is $0.0 B at a stock price of $11.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is Spok Holdings, Inc.'s P/E ratio?

Spok Holdings, Inc. trades at a P/E of 19.6×, at the 74th percentile of its own 1-year range, against a long-run median of 17.9×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does Spok Holdings, Inc. pay a dividend?

Yes — Spok Holdings, Inc. declared $0.31 per share for Mar 26, and $1.25 per share across the last four reported quarters. — as of 5 August 2026.

What is Spok Holdings, Inc.'s dividend per share?

Spok Holdings, Inc.'s most recently declared dividend is $0.31 per share for Mar 26, giving $1.25 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.

What is Spok Holdings, Inc.'s dividend yield?

Spok Holdings, Inc.'s trailing dividend yield is 11.15%: $1.25 declared per share across the last four reported quarters, against a share price of $11.2. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.

Is Spok Holdings, Inc. overvalued?

On its own history, Spok Holdings, Inc. looks expensive against its own history: its P/E of 19.6× sits at the 74th percentile of its 1-year range (long-run median 17.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.

Is Spok Holdings, Inc. growing?

Not right now — Spok Holdings, Inc.'s latest numbers are shrinking: latest-quarter revenue −25.0% year on year, profit −100.0%, and the margin −25.0 pp at 0.0%. The earnings engine currently reads: deteriorating — as of 5 August 2026.

How is Spok Holdings, Inc. performing?

Spok Holdings, Inc.'s latest readings are below. Its latest quarter's revenue fell 25.0% and profit fell 100.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 24 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Spok Holdings, Inc. in?

Mixed — no clean majority across the growth curves, ROCE slipping at 6.5% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +0.0% latest, eps growth −23.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Spok Holdings, Inc. beating the market?

Not lately — on a trailing-13-week view Spok Holdings, Inc. is currently behind the S&P 500 (24 weeks and counting; last ahead the week of 2026-02-20), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved −36% against the S&P 500's +24% — behind the index over the full window. — as of 5 August 2026.

Will Spok Holdings, Inc.'s stock price go up?

This page publishes no price forecast for Spok Holdings, Inc. What it measures instead: the stock price is $11.2. Its P/E of 19.6× sits at the 74th percentile of its own 1-year range. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Spok Holdings, Inc.?

Somewhat — short interest is 3.1% of Spok Holdings, Inc.'s tradable float, about 2.9 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does Spok Holdings, Inc. have too much debt?

No — Spok Holdings, Inc.'s debt-to-equity is 0.04. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.

What is Spok Holdings, Inc.'s capex?

Spok Holdings, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.

What is Spok Holdings, Inc.'s cash flow?

Spok Holdings, Inc. generated $0.0 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is Spok Holdings, Inc.'s profit real cash?

Yes — over the last 3 fiscal years, 180% of Spok Holdings, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.0 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is Spok Holdings, Inc.?

On the balance sheet, the Z-score reads 4.36 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.

Where is Spok Holdings, Inc. in its business cycle?

Spok Holdings, Inc.'s FY25 operating margin was 14.3%, against a 5-year band of −21.4%–14.3%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 0.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Spok Holdings, Inc. story?

The sharpest disagreement: annual EPS moved +2.7% against a −39.4% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Spok Holdings, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Spok Holdings, Inc. is printing record margins on a fuller multiple. From here the earnings must do all the lifting. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI